Other Corporate Information – Page 10

2024-11-112024-11-11

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Alligator Bioscience and Aptevo Therapeutics report favorable safety, tolerability and evidence of biological activity of ALG.APV-527, with ...

2024-11-06

The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trial Conf ...

2024-10-30

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces participation in the following conferences during Q4 202 ...

2024-10-29

LUND, SWEDEN and SEATTLE WA / October 29, 2024 / Alligator Bioscience AB (“Alligator”) (ATORX) and Aptevo Therapeutics (“A ...

2024-09-16

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrate ...

2024-09-13

Lund, Sweden and Seattle, Washington, September 13, 2024 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) ...

2024-07-10

Recruitment completed for the additional cohort with 450 µg/kg of mitazalimab in combination with mFOLFIRINOX as requested by FDA ahea ...

2024-06-26

Regulatory

Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously repo ...

2024-06-25

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...